[{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Aptevo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jade Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jade Biosciences \/ Jade Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Jade Biosciences \/ Jade Biosciences"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Jade Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Jade Biosciences \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"2","companyTruncated":"Jade Biosciences \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Aerovate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Merger","leadProduct":"JADE-001","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Jade Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jade Biosciences \/ Jade Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Jade Biosciences \/ Jade Biosciences"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Aerovate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Merger","leadProduct":"JADE-001","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Jade Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jade Biosciences \/ Jade Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Jade Biosciences \/ Jade Biosciences"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Aerovate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Merger","leadProduct":"JADE-001","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Jade Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jade Biosciences \/ Jade Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Jade Biosciences \/ Jade Biosciences"}]